NCT04065399: An ongoing trial by Syndax Pharmaceuticals
This trial is ongoing. It must report results 2 years, 12 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04065399 |
|---|---|
| Title | A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 5, 2019 |
| Completion date | Dec. 15, 2027 |
| Required reporting date | Dec. 14, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |